Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cassava Sciences, Inc. - Common Stock (NQ:SAVA)

2.140 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cassava Sciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
37 38 Next >
Benzinga Bulls And Bears: Amazon, Tesla, Rivian, Palantir And How Dogecoin Helped Low-Income Families Achieve Homeownership
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories. 
Via Benzinga
Unpacking the Latest Options Trading Trends in Cassava Sciences
 
Via Benzinga
This Goldman Sachs Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
 
Via Benzinga
Cassava Sciences, Zoom, Kohl's, Rivian, Tesla: Why These 5 Stocks Are On Investors' Radars Today
SAVA, ZM, KSS, RIVN, TSLA were among the trending stocks among investors on Monday Nov. 25, 2024. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Unpacking the Latest Options Trading Trends in Cassava Sciences
 
Via Benzinga
How Is The Market Feeling About Cassava Sciences?
 
Via Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth $20,000 Today
 
Via Benzinga
Gold Down Over 3%; Rigetti Computing Shares Spike Higher
 
Via Benzinga
Crude Oil Down 3%; Chicago Fed National Activity Index Falls In October
 
Via Benzinga
Topics Economy
'Pharma Bro' Martin Shkreli Tells Investors To 'Short SAVA,' Stock Falls Over 80% After Phase 3 Update
Pharma bro Martin Shkreli predicted Cassava Sciences stock would fall and the company would miss primary endpoints for its Phase 3 trial. 
Via Benzinga
Dow Surges Over 300 Points; Bath & Body Works Posts Upbeat Earnings
 
Via Benzinga
Topics Stocks
Cassava Sciences Alzheimer's Drug Fails To Hit Primary Goal In Pivotal Study, Pharma Halts Late-Stage Studies
Cassava Sciences' stock fell after Phase 3 simufilam trial failed to meet key endpoints, prompting the discontinuation of its Alzheimer's studies. 
Via Benzinga
Cassava Sciences Plummets 85% After Embattled Alzheimer's Drug Flops
The company tested simufilam in patients with mild-to-moderate Alzheimer's disease. 
Via Investor's Business Daily
Cassava Sciences, Biohaven And Other Big Stocks Moving Lower In Monday's Pre-Market Session
 
Via Benzinga
Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary Endpoints
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences to Hold Corporate Update on November 25th
Webcast planned for Monday, November 25th at 8:00 AM ET 
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer
From Cassava Sciences, Inc.
Via GlobeNewswire
Friday's Top 5 Trending Stocks: What's The Scoop On GameStop, SoFi, Tesla?
GameStop, SoFi, Tesla, Cassava Sciences and Anavex Life Sciences are the top five trending stocks on Stocktwits Friday. Here's a look at what's going on: 
Via Benzinga
Cassava Sciences Reports Q3 2024 Financial and Operating Results
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024
Conference call and webcast to begin at 8:30 AM ET 
From Cassava Sciences, Inc.
Via GlobeNewswire
Analysts Believe Cassava Sciences Now Has 300% Upside From Here
Cassava Sciences faces controversy over its Alzheimer's drug, simufilam, amid fraud allegations, yet analysts maintain a Buy rating with high upside potential. 
Via MarketBeat
Topics Fraud Lawsuit
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Crude Oil Falls Over 4%; US Trade Deficit Narrows In August
 
Via Benzinga
What's Going On With Alzheimer's-Focused Cassava Sciences On Tuesday?
Cassava Sciences Inc. has agreed to a $40 million settlement over SEC charges related to misleading data for simufilam. The firm anticipates top-line results from the ReTHINK Phase 3 trial before... 
Via Benzinga
Topics Regulatory Compliance
PepsiCo, DocuSign, Robinhood And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
This Wells Fargo Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
 
Via Benzinga
Nano-Cap Bio-Path Takes Plunge In Weight Loss Race, Initiates Obesity Program With Drug Candidate Under Development For Blood Cancer
Bio-Path is advancing its obesity treatment BP1001-A and completing trials for BP1002 in acute myeloid leukemia, targeting resistance mechanisms in treatment. Preclinical studies for obesity are set... 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Why Cassava Sciences Stock Dived by Almost 11% Today
Without admitting wrongdoing, the company put a regulatory controversy to rest, but this was expensive. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
37 38 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback